Incyte Corp (INCY)

Jan 15, 2025, 5:34 PM EST - 2 days ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

SNDX

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 13, 2025, 8:30 AM EST - 4 days ago

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 11, 2025, 9:30 AM EST - 6 days ago

Incyte: Multiple Drug Launches Bode Well For Future Growth

Jan 8, 2025, 6:30 PM EST - 9 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 8:00 AM EST - 4 weeks ago

Incyte to Present at Upcoming Investor Conference

Dec 10, 2024, 10:30 AM EST - 5 weeks ago

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Dec 7, 2024, 7:30 AM EST - 5 weeks ago

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Nov 26, 2024, 4:10 PM EST - 7 weeks ago

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Nov 25, 2024, 10:09 AM EST - 7 weeks ago

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Nov 19, 2024, 12:51 PM EST - 2 months ago

Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study

Nov 19, 2024, 12:21 PM EST - 2 months ago

Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.

Nov 19, 2024, 12:18 PM EST - 2 months ago

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

Nov 18, 2024, 4:30 PM EST - 2 months ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Oct 31, 2024, 7:41 AM EDT - 2 months ago

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 30, 2024, 4:37 PM EDT - 2 months ago

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock

Oct 30, 2024, 8:00 AM EDT - 2 months ago

Incyte to Present at Upcoming Investor Conferences

Oct 29, 2024, 1:30 PM EDT - 2 months ago

Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 12:07 PM EDT - 2 months ago

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

Oct 29, 2024, 9:22 AM EDT - 2 months ago

Incyte raises 2024 sales forecast for top-selling drug Jakafi

Oct 29, 2024, 7:00 AM EDT - 2 months ago

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Oct 24, 2024, 2:03 PM EDT - 3 months ago

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

Oct 10, 2024, 9:15 AM EDT - 3 months ago

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

Oct 8, 2024, 8:00 AM EDT - 3 months ago

Incyte to Report Third Quarter Financial Results

Oct 3, 2024, 4:30 PM EDT - 3 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2024, 7:00 AM EDT - 4 months ago

Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

Sep 18, 2024, 5:15 PM EDT - 4 months ago

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

SNDX

Sep 18, 2024, 2:44 PM EDT - 4 months ago

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets

Sep 15, 2024, 1:30 AM EDT - 4 months ago

Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects

Sep 14, 2024, 12:45 PM EDT - 4 months ago

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Sep 14, 2024, 10:30 AM EDT - 4 months ago

Incyte's Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

Aug 21, 2024, 11:40 AM EDT - 5 months ago

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 19, 2024, 3:04 PM EDT - 5 months ago

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 16, 2024, 9:29 AM EDT - 5 months ago

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study

Aug 15, 2024, 7:09 PM EDT - 5 months ago

Incyte's blood cancer drug succeeds late-stage trial

Aug 15, 2024, 4:30 PM EDT - 5 months ago

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma